Top

Current Psychiatry Reports

Published in:

Open Access 01-08-2020 | Suicide | Personality Disorders (K Bertsch, Section Editor)

Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies

Authors: Jutta Stoffers-Winterling, Ole Jakob Storebø, Klaus Lieb

Published in: Current Psychiatry Reports | Issue 8/2020

Abstract

Purpose of the Review

We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.

Recent Findings

We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others.

Summary

The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.

NHMRC. Clinical practice guideline for the management of borderline personality disorder [Internet]. Canberra: National Health and Medical Research Council; 2013 [cited 2016 Dec 1]. Available from: http://www.nhmrc.gov.au/guidelines/publications/mh25

NICE National Institute for Health and Care Excellence. 2018 Surveillance of personality disorders (NICE guidelines CG77 and CG78). Surveillance report. Published 19 July 2018. Available from https://www.nice.org.uk/guidance/cg78/resources/2018-surveillance-of-personality-disorders-nice-guidelines-cg77-and-cg78-4906490080/chapter/Surveillance-decision?tab=evidence. 2018.

Stoffers JM, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev [Internet]. 2012; Available from: ://WOS:000308220400007.

Storebø OJ, Stoffers-Winterling JM, Völlm BA, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020;5(5):CD012955. https://doi.org/10.1002/14651858.CD012955.pub2.

Oud M, Arntz A, Hermens ML, Verhoef R, Kendall T. Specialized psychotherapies for adults with borderline personality disorder: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;4867418791257.

Cristea IA, Gentili C, Cotet CD, Palomba D, Barbui C, Cuijpers P. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:319–28.CrossRef

Zanarini MC, Frankenburg FR, Reich DB, Conkey LC, Fitzmaurice GM Treatment rates for patients with borderline personality disorder and other personality disorders: a 16-year study. Psychiatr Serv [Internet]. 2015 [cited 2017 Jun 20]; Available from: http://ps.psychiatryonline.org/doi/abs/10.1176/appi.ps.201400055?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Bridler R, Haberle A, Muller ST, Cattapan K, Grohmann R, Toto S, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25:763–72.CrossRef

Paris J. Why patients with severe personality disorders are overmedicated. J Clin Psychiatry. 2015;76:e521.CrossRef

10.

Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder-current evidence and recent trends. Curr Psychiatry Rep. 2015;17:534.CrossRef

11.

• Bozzatello P, Rocca P, Uscinska M, Bellino S. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial. CNS Drugs. 2017;31:809–19 This RCT compared the two second-generation antipsychotics olanzapine and azenapine but found no clear superiority of any of the substances. Total efficacy of both agents in people with BPD unclear.

12.

•• Crawford M, Sanatinia R, Barrett B, Cunningham G, Dale O, Ganguli P, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018;175:756–64 A large-scale, pragmatic RCT. No effects were detected in this effectiveness trial. The long observation period of one year and the broad eligibility criteria for participants grant the findings applicable to routine care.

13.

• Kulkarni J, Thomas N, Hudaib A-R, Gavrilidis E, Grigg J, Tan R, et al. Effect of the glutamate NMDA receptor antagonist Memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial. CNS Drugs. 2018;32:179–87 Small experiential RCT testing an anti-dementia drug. Authors report higher rate of change of BPD severity by memantine.

14.

• Lee SS, Allen J, Black DW, Zanarini MC, Schulz SC. Quetiapine’s effect on the SCL-90-R domains in patients with borderline personality disorder. Ann Clin Psychiatry Off J Am Acad Clin Psychiatry. 2016;28:4–10 Additional data relating to [16].

15.

•• Crawford MJ, Sanatinia R, Barrett B, Cunningham G, Dale O, Ganguli P, et al. Lamotrigine for people with borderline personality disorder: a RCT. Health Technol Assess Winch Engl. 2018;22:1–68 Comprehensive study report of [12]. CrossRef

16.

• Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171:1174–82 First and only RCT of quetiapine in people in BPD. New data of this study have been published in [17] and [14]. CrossRef

17.

• Seroquel extended release (XR) for the management of borderline personality disorder (BPD) - study results - ClinicalTrials.gov [Internet]. [cited 2020 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00880919Study register entry of [16] with study results.

18.

• Comparing treatments for self-injury and suicidal behavior in people with borderline personality disorder - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Mar 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00834834Study register entry with study results. Results have not been published elsewhere.

19.

• Treating suicidal behavior and self-mutilation in people with borderline personality disorder - study results - ClinicalTrials.gov [Internet]. [cited 2020 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00533117Study register entry with study results. Results have not been published elsewhere.

20.

• Preliminary trial of the effect of glucocorticoid receptor antagonist on borderline personality disorder (BPD) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Apr 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT01212588Experiential trial of mifepristone. The findings do not support the use of this agent.

21.

• N-Acetylcysteine in adjunct to DBT for the treatment of self-injurious behavior in BPD - study results - ClinicalTrials.gov [Internet]. [cited 2020 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00539188Early-terminated RCT due to recruiting problems, study results reported for a very small number of participants.

22.

DBT and escitalopram in borderline personality disorder - tabular view - ClinicalTrials.gov [Internet]. [cited 2020 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT00255554

23.

NCT01103180, University of C, Temple U, Northwestern U, University of Southern M. Selective serotonin reuptake inhibitors (SSRIs) in borderline personality disorder. 2010; Available from: http://clinicaltrials.gov/show/NCT01103180

24.

Clinical research study to evaluate selegiline in the treatment of borderline personality disorder - full text view - ClinicalTrials.gov [Internet]. [cited 2014 Jun 24]. Available from: http://clinicaltrials.gov/show/NCT01912391

25.

Simpson E, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379–85.CrossRef

26.

Zanarini MC, Frankenburg FR, Reich DB, Harned AL, Fitzmaurice GM. Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. J Clin Psychopharmacol. 2015;35:63–7.CrossRef

27.

Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76:e512–8.CrossRef

28.

Martin-Blanco A, Ancochea A, Soler J, Elices M, Carmona C, Pascual J. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand. 2017;136:323–31.CrossRef

29.

Riffer F, Farkas M, Streibl L, Kaiser E, Sprung M. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract. 2019;23:178–88.CrossRef

30.

Ingenhoven T. Pharmacotherapy for borderline patients: business as usual or by default? J Clin Psychiatry. 2015;76:522–3.CrossRef

31.

Stoffers JM, Völlm BA, Rücker G, Timmer A, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev Online. 2010;6.

32.

Brexpiprazole in borderline personality disorder - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Apr 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03418675

33.

A trial of brexpiprazole in the treatment of borderline personality disorder - tabular view - ClinicalTrials.gov [Internet]. [cited 2020 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04100096

34.

ISRCTN - ISRCTN18352058: Clozapine in the treatment of borderline personality disorder. The CALMED study. [Internet]. [cited 2020 Mar 31]. Available from: http://www.isrctn.com/ISRCTN18352058

35.

ACTRN12616001192471. VERBATIM: A randomised controlled trial of aripiprazole for the treatment of auditory verbal hallucinations in borderline personality disorder [Internet]. [cited 2018 Sep 16]. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371038

36.

Paolini E, Mezzetti FAF, Pierri F, Moretti P. Pharmacological treatment of borderline personality disorder: a retrospective observational study at inpatient unit in Italy. Int J Psychiatry Clin Pract. 2017;21:75–9.CrossRef

37.

NCT00254748. Verkes borderline study: the effect of quetiapine on borderline personality disordered patients [Internet]. [cited 2018 Sep 16]. Available from: https://ClinicalTrials.gov/show/NCT00254748

38.

ISRCTN11135486 - Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study [Internet]. [cited 2014 Jun 13]. Available from: http://www.controlled-trials.com/ISRCTN11135486

39.

Low-dose risperidone treatment for subjects suffering from borderline personality disorder - tabular view - ClinicalTrials.gov [Internet]. [cited 2020 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT00633802

40.

Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry J Ment Sci. 2010;196:4–12.CrossRef

41.

Feurino L, Silk KR. State of the art in the pharmacologic treatment of borderline personality disorder. Curr Psychiatry Rep. 2011;13:69–75.CrossRef

42.

Abraham PF, Calabrese JR. Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord. 2008;111:21–30.CrossRef

43.

Moen R, Freitag M, Miller M, Lee S, Romine A, Song S, et al. Efficacy of extended-release divalproex combined with “condensed” dialectical behavior therapy for individuals with borderline personality disorder. Ann Clin Psychiatry. 2012;24:255–60.PubMed

44.

Hoerst M, Weber-Fahr W, Tunc-Skarka N, Ruf M, Bohus M, Schmahl C, et al. Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch Gen Psychiatry. 2010;67:946–54.CrossRef

45.

Ketamine in borderline personality disorder - tabular view - ClinicalTrials.gov [Internet]. [cited 2020 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03395314

46.

Botulinum toxin A for emotional stabilization in borderline personality disorder (BPD) - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Apr 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02728778

47.

Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23–9.CrossRef

48.

Rinne T, van den Brink W, Wouter L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048–54.CrossRef

49.

Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193:485–92.CrossRef

50.

Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72:1353–62.CrossRef

51.

Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatry Clin North Am. 2018;41:583–93.CrossRef

52.

Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. Attainment and stability of sustained symptomatic remission and recovery among borderline patients and axis II comparison subjects: a 16-year prospective follow-up study. Am J Psychiatry. 2012;169:476–83.CrossRef

53.

Stoffers-Winterling JM, Storebø OJ, Völlm BA, Mattivi JT, Nielsen SS, Kielsholm ML, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev [Internet]. 2018 [cited 2018 Aug 20]; Available from: https://doi.org/10.1002/14651858.CD012956/abstract

Title: Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies
Authors: Jutta Stoffers-Winterling
Ole Jakob Storebø
Klaus Lieb
Publication date: 01-08-2020
Publisher: Springer US
Keywords: Suicide
Antidepressant Drugs
Suicide
Borderline Personality Disorder
Antipsychotics
Antidepressant Drugs
Fluoxetine
Antipsychotics
Asenapine
Olanzapine
Quetiapine
Lamotrigine
Published in: Current Psychiatry Reports / Issue 8/2020
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-020-01164-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies

Abstract

Purpose of the Review

Recent Findings

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of the Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 8/2020

The Role of Anxiety in Smoking Onset, Severity, and Cessation-Related Outcomes: a Review of Recent Literature

Children’s Reactions to Media Coverage of War

Personality Disorders in the ICD-11: Opportunities and Challenges for Advancing the Diagnosis of Personality Pathology

Children’s Exposure to Single Incidents of Terrorism: Perspectives Over 25 Years Since the Oklahoma City Bombing

Neuropsychiatric Correlates of Narcolepsy

The Psychological Impact of Epidemic and Pandemic Outbreaks on Healthcare Workers: Rapid Review of the Evidence